143 related articles for article (PubMed ID: 37099955)
1. Outpatient care concept and potential inpatient cost savings associated with the administration of dalbavancin - A real-world data and retrospective cost analysis.
Baltin CT; Wulf C; Rongisch R; Lehmann C; Wingen-Heimann S; Eisenmenger N; Bonn J; Fabri M; von Stebut E; Cornely OA; Kron F
J Infect Public Health; 2023 Jun; 16(6):955-963. PubMed ID: 37099955
[TBL] [Abstract][Full Text] [Related]
2. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting.
Ektare V; Khachatryan A; Xue M; Dunne M; Johnson K; Stephens J
J Med Econ; 2015; 18(12):1092-101. PubMed ID: 26368787
[TBL] [Abstract][Full Text] [Related]
3. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.
Turco NJ; Kane-Gill SL; Hernandez I; Oleksiuk LM; D'Amico F; Pickering AJ
Expert Opin Pharmacother; 2018 Mar; 19(4):319-325. PubMed ID: 29509504
[TBL] [Abstract][Full Text] [Related]
4. Financial Analysis of Dalbavancin for Acute Bacterial Skin and Skin Structure Infections for Self-Pay Patients.
Pizzuti AG; Murray EY; Wagner JL; Gaul DA; Bland CM; Jones BM
Infect Dis Ther; 2020 Dec; 9(4):1043-1053. PubMed ID: 33083894
[TBL] [Abstract][Full Text] [Related]
5. Single Intravenous Dose Dalbavancin Pathway for the Treatment of Acute Bacterial Skin and Skin Structure Infections: Considerations for Emergency Department Implementation and Cost Savings.
LoVecchio F; McCarthy MW; Ye X; Henry AD; Doan QV; Lock JL; Riccobene T; Lyles RD; Talan DA
J Emerg Med; 2024 Mar; ():. PubMed ID: 38825531
[TBL] [Abstract][Full Text] [Related]
6. Economic Impact of Oritavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in the Emergency Department or Observation Setting: Cost Savings Associated with Avoidable Hospitalizations.
Lodise TP; Fan W; Sulham KA
Clin Ther; 2016 Jan; 38(1):136-48. PubMed ID: 26708118
[TBL] [Abstract][Full Text] [Related]
7. Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries.
Marcellusi A; Bini C; Andreoni M; Sarmati L; Espin J; Horcajada JP; Czypionka T; Andretta D; Sciattella P; Favato G; Mennini FS
Clin Drug Investig; 2020 Apr; 40(4):305-318. PubMed ID: 32034687
[TBL] [Abstract][Full Text] [Related]
8. Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections.
Rappo U; Gonzalez PL; Puttagunta S; Akinapelli K; Keyloun K; Gillard P; Liu Y; Dunne MW
J Glob Antimicrob Resist; 2019 Jun; 17():60-65. PubMed ID: 30797084
[TBL] [Abstract][Full Text] [Related]
9. REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI.
Papavramidis T; Gentile I; Cattelan AM; Magnasco L; Viale P; Francisci D; Kofteridis DP; Tiseo G; Giamarellos-Bourboulis EJ; Lagi F; Pinna SM; D'Amico F; La Ferla L; Panagopoulos P; Gattuso G; Sipsas NV; Ruggieri A; Cattaneo A; Corio L; Comandini A; Mascagni P; Bassetti M
Int J Antimicrob Agents; 2023 Apr; 61(4):106746. PubMed ID: 36758778
[TBL] [Abstract][Full Text] [Related]
10. Cost-Consequence Analysis of Single-Dose Dalbavancin Versus Standard of Care for the Treatment of Acute Bacterial Skin and Skin Structure Infections in a Multisite Healthcare System.
Gonzalez J; Andrade DC; Niu J
Clin Infect Dis; 2021 Oct; 73(7):e1436-e1442. PubMed ID: 33211794
[TBL] [Abstract][Full Text] [Related]
11. Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis.
Jensen IS; Lodise TP; Fan W; Wu C; Cyr PL; Nicolau DP; DuFour S; Sulham KA
Clin Drug Investig; 2016 Feb; 36(2):157-68. PubMed ID: 26692006
[TBL] [Abstract][Full Text] [Related]
12. Potential savings through single-dose intravenous Dalbavancin in long-term MRSA infection treatment - a health economic analysis using German DRG data.
Wilke M; Worf K; Preisendörfer B; Heinlein W; Kast T; Bodmann KF
GMS Infect Dis; 2019; 7():Doc03. PubMed ID: 31728264
[TBL] [Abstract][Full Text] [Related]
13. Modeling operational quality metrics and costs of long-acting antibiotics for acute bacterial skin and skin structure infection treatment in the emergency department.
Keyloun KR; Lofgren E; Hebert S
J Med Econ; 2019 Jul; 22(7):652-661. PubMed ID: 30838908
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study).
Bai F; Aldieri C; Cattelan A; Raumer F; Di Meco E; Moioli MC; Tordato F; Morelli P; Borghi F; Rizzi M; Van Hauwermeiren E; Castelli F; Migliorino G; Menzaghi B; Rizzardini G; Saracino A; Cascio A; Puoti M; d'Arminio Monforte A; Marchetti G
Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1271-1279. PubMed ID: 32797758
[TBL] [Abstract][Full Text] [Related]
15. Length of Stay and Costs with Autologous Skin Cell Suspension Versus Split-Thickness Skin Grafts: Burn Care Data from US Centers.
Carter JE; Carson JS; Hickerson WL; Rae L; Saquib SF; Wibbenmeyer LA; Becker RV; Walsh TP; Sparks JA
Adv Ther; 2022 Nov; 39(11):5191-5202. PubMed ID: 36103088
[TBL] [Abstract][Full Text] [Related]
16. Budget Impact Model of Omadacycline on Replacing a Proportion of Existing Treatment Options Among Patients Who Present to the Emergency Department with Acute Bacterial Skin and Skin Structure Infections.
LaPensee K; Mistry R; Lodise T
Am Health Drug Benefits; 2019 Feb; 12(1-Supplement 2):S13-S24. PubMed ID: 30996767
[TBL] [Abstract][Full Text] [Related]
17. Impact of transitioning inpatient chemotherapy regimens to the outpatient setting.
Corsi MP; Shea K; W Knoebel R
J Oncol Pharm Pract; 2020 Sep; 26(6):1324-1330. PubMed ID: 31822200
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) from the national payer perspective: introduction of a new treatment to the patient journey. A simulation of three European countries.
Marcellusi A; Viti R; Sciattella P; Sarmati L; Streinu-Cercel A; Pana A; Espin J; Horcajada JP; Favato G; Andretta D; Soro M; Andreoni M; Mennini FS
Expert Rev Pharmacoecon Outcomes Res; 2019 Oct; 19(5):581-599. PubMed ID: 30714834
[No Abstract] [Full Text] [Related]
19. Potential Cost-Savings with Once-Daily Aminomethylcycline Antibiotic versus Vancomycin in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections.
LaPensee K; Lodise T
Am Health Drug Benefits; 2018 Dec; 11(9):449-459. PubMed ID: 30746017
[TBL] [Abstract][Full Text] [Related]
20. Economic burden of hospital admissions for patients with acute bacterial skin and skin structure infections in the United States.
Keyloun KR; Weber DJ; Gardstein BM; Berger A; Gillard P; Ganz ML
Hosp Pract (1995); 2018 Dec; 46(5):278-286. PubMed ID: 30067108
[No Abstract] [Full Text] [Related]
[Next] [New Search]
